Home  |  Contact

Cellosaurus Reh (CVCL_1650)

[Text version]

Cell line name Reh
Synonyms REH
Accession CVCL_1650
Resource Identification Initiative To cite this cell line use: Reh (RRID:CVCL_1650)
Comments Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: COSMIC cell lines project.
Part of: LL-100 blood cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Doubling time: 34.7 hours (PubMed=8847894); 30 hours (PubMed=25984343); ~50-70 hours (DSMZ).
Microsatellite instability: Instable (MSI-high) (PubMed=31068700; Sanger).
Omics: Array-based CGH.
Omics: Deep antibody staining analysis.
Omics: Deep exome analysis.
Omics: Deep quantitative phosphoproteome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Derived from sampling site: Peripheral blood.
Sequence variations ETV6-RUNX1 (TEL-AML1) gene fusion (PubMed=9067587; PubMed=15843827).
Genome ancestry Source: PubMed=30894373

Origin% genome
African21.18
Native American0.09
East Asian, North1.57
East Asian, South2
South Asian1.52
European, North15.6
European, South58.04
Disease Childhood B acute lymphoblastic leukemia (NCIt: C9140)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_8857 (EU-1)CVCL_0011 (KM-3)CVCL_8462 (NOI-90)
CVCL_A049 (WSU-CLL)
Sex of cell Female
Age at sampling 15Y
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX
CSF1PO10,11,12 (AddexBio; ATCC; PubMed=25877200)
12,13 (CLS; Cosmic-CLP; DSMZ)
D3S135818
D5S81811,13 (AddexBio; ATCC; PubMed=25877200)
11,12,13 (CLS)
11,12 (Cosmic-CLP; DSMZ)
D7S8209,12 (AddexBio; ATCC; Cosmic-CLP; DSMZ; PubMed=25877200)
9,10,12,13 (CLS)
D8S117913,14,16,17 (CLS)
13,15 (PubMed=25877200)
D13S31711,13 (AddexBio; ATCC; PubMed=25877200)
11,12,13 (CLS)
11,14 (Cosmic-CLP)
10,11,14 (DSMZ)
D16S5399 (AddexBio; ATCC; PubMed=25877200)
9,10,12,13 (CLS)
9,13 (Cosmic-CLP; DSMZ)
D18S5110,11,14 (CLS)
10,14 (PubMed=25877200)
D21S1128,29,30,31 (CLS)
28,30 (PubMed=25877200)
FGA22,23,24 (CLS)
22,23 (PubMed=25877200)
Penta D9,12 (CLS)
9,11 (PubMed=25877200)
Penta E10,11 (CLS)
7,11 (PubMed=25877200)
TH017 (AddexBio; ATCC; CLS; PubMed=25877200)
7,9 (Cosmic-CLP; DSMZ)
TPOX8
vWA14,15 (AddexBio; ATCC; Cosmic-CLP; PubMed=25877200)
14,15,16 (CLS; DSMZ)

Run an STR similarity search on this cell line
Web pages http://www.proteinatlas.org/learn/cellines
http://tcpaportal.org/mclp/
http://www.cellresource.cn/fdetail.aspx?id=699
Publications

PubMed=197411; DOI=10.1038/267841a0
Rosenfeld C., Goutner A., Choquet C., Venuat A.M., Kayibanda B., Pico J.L., Greaves M.F.
Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line.
Nature 267:841-843(1977)

DOI=10.1007/BF00204739
Bertoglio J., Guibout C., Dore J.-F., Rosenfeld C.
Further characterization of a non-T, non-B acute lymphoblastic leukaemia cell line (Reh). Reactivity with human sera cytotoxic for leukaemia cells.
Cancer Immunol. Immunother. 4:193-196(1978)

PubMed=2140233; DOI=10.1111/j.1440-1827.1990.tb01549.x
Nakano A., Harada T., Morikawa S., Kato Y.
Expression of leukocyte common antigen (CD45) on various human leukemia/lymphoma cell lines.
Acta Pathol. Jpn. 40:107-115(1990)

PubMed=7630190
Zhou M., Gu L., James C.D., He J., Yeager A.M., Smith S.D., Findley H.W.
Homozygous deletions of the CDKN2 (MTS1/p16ink4) gene in cell lines established from children with acute lymphoblastic leukemia.
Leukemia 9:1159-1161(1995)

PubMed=7888679
Zhou M., Yeager A.M., Smith S.D., Findley H.W.
Overexpression of the MDM2 gene by childhood acute lymphoblastic leukemia cells expressing the wild-type p53 gene.
Blood 85:1608-1614(1995)

PubMed=8847894
Tani A., Tatsumi E., Nakamura F., Kumagai S., Kosaka Y., Sano K., Nakamura H., Amakawa R., Ohno H.
Sensitivity to dexamethasone and absence of bcl-2 protein in Burkitt's lymphoma cell line (Black93) derived from a patient with acute tumor lysis syndrome: comparative study with other BL and non-BL lines.
Leukemia 10:1592-1603(1996)

PubMed=9067587; DOI=10.1038/sj.leu.2400571
Uphoff C.C., MacLeod R.A.F., Denkmann S.A., Golub T.R., Borkhardt A., Janssen J.W.G., Drexler H.G.
Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
Leukemia 11:441-447(1997)

PubMed=9108419
Findley H.W., Gu L., Yeager A.M., Zhou M.
Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia.
Blood 89:2986-2993(1997)

PubMed=9510473; DOI=10.1111/j.1349-7006.1998.tb00476.x
Hosoya N., Hangaishi A., Ogawa S., Miyagawa K., Mitani K., Yazaki Y., Hirai H.
Frameshift mutations of the hMSH6 gene in human leukemia cell lines.
Jpn. J. Cancer Res. 89:33-39(1998)

PubMed=9680106; DOI=10.1016/S0145-2126(98)00050-2
Matsuo Y., Drexler H.G.
Establishment and characterization of human B cell precursor-leukemia cell lines.
Leuk. Res. 22:567-579(1998)

PubMed=9823951; DOI=10.1038/sj.leu.2401198
Zhou M., Gu L., Yeager A.M., Findley H.W.
Sensitivity to Fas-mediated apoptosis in pediatric acute lymphoblastic leukemia is associated with a mutant p53 phenotype and absence of Bcl-2 expression.
Leukemia 12:1756-1763(1998)

PubMed=10490826; DOI=10.1038/sj.onc.1202874
Fu X., McGrath S., Pasillas M., Nakazawa S., Kamps M.P.
EB-1, a tyrosine kinase signal transduction gene, is transcriptionally activated in the t(1;19) subset of pre-B ALL, which express oncoprotein E2a-Pbx1.
Oncogene 18:4920-4929(1999)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In) ISBN 9780122219702; pp.1-733; Academic Press; London (2001)

PubMed=14504097; DOI=10.1182/blood-2003-02-0418
Taketani T., Taki T., Sugita K., Furuichi Y., Ishii E., Hanada R., Tsuchida M., Sugita K., Ida K., Hayashi Y.
FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy.
Blood 103:1085-1088(2004)

PubMed=15843827; DOI=10.1038/sj.leu.2403749
Andersson A., Eden P., Lindgren D., Nilsson J., Lassen C., Heldrup J., Fontes M., Borg A., Mitelman F., Johansson B., Hoglund M., Fioretos T.
Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations.
Leukemia 19:1042-1050(2005)

PubMed=16408098; DOI=10.1038/sj.leu.2404081
Quentmeier H., MacLeod R.A.F., Zaborski M., Drexler H.G.
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders.
Leukemia 20:471-476(2006)

PubMed=16523483; DOI=10.1002/gcc.20317
Horsley S.W., Mackay A., Iravani M., Fenwick K., Valgeirsson H., Dexter T., Ashworth A., Kearney L.
Array CGH of fusion gene-positive leukemia-derived cell lines reveals cryptic regions of genomic gain and loss.
Genes Chromosomes Cancer 45:554-564(2006)

PubMed=20164919; DOI=10.1038/nature08768
Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)

PubMed=21552520; DOI=10.1371/journal.pone.0019169
Gu T.-L., Nardone J., Wang Y., Loriaux M., Villen J., Beausoleil S., Tucker M., Kornhauser J., Ren J., MacNeill J., Gygi S.P., Druker B.J., Heinrich M.C., Rush J., Polakiewicz R.D.
Survey of activated FLT3 signaling in leukemia.
PLoS ONE 6:E19169-E19169(2011)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

PubMed=30285677; DOI=10.1186/s12885-018-4840-5
Tan K.-T., Ding L.-W., Sun Q.-Y., Lao Z.-T., Chien W., Ren X., Xiao J.-F., Loh X.-Y., Xu L., Lill M., Mayakonda A., Lin D.-C., Yang H., Koeffler H.P.
Profiling the B/T cell receptor repertoire of lymphocyte derived cell lines.
BMC Cancer 18:940-940(2018)

PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747
Dutil J., Chen Z., Monteiro A.N., Teer J.K., Eschrich S.A.
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Cancer Res. 79:1263-1273(2019)

PubMed=31068700; DOI=10.1038/s41586-019-1186-3
Ghandi M., Huang F.W., Jane-Valbuena J., Kryukov G.V., Lo C.C., McDonald E.R. III, Barretina J., Gelfand E.T., Bielski C.M., Li H., Hu K., Andreev-Drakhlin A.Y., Kim J., Hess J.M., Haas B.J., Aguet F., Weir B.A., Rothberg M.V., Paolella B.R., Lawrence M.S., Akbani R., Lu Y., Tiv H.L., Gokhale P.C., de Weck A., Mansour A.A., Oh C., Shih J., Hadi K., Rosen Y., Bistline J., Venkatesan K., Reddy A., Sonkin D., Liu M., Lehar J., Korn J.M., Porter D.A., Jones M.D., Golji J., Caponigro G., Taylor J.E., Dunning C.M., Creech A.L., Warren A.C., McFarland J.M., Zamanighomi M., Kauffmann A., Stransky N., Imielinski M., Maruvka Y.E., Cherniack A.D., Tsherniak A., Vazquez F., Jaffe J.D., Lane A.A., Weinstock D.M., Johannessen C.M., Morrissey M.P., Stegmeier F., Schlegel R., Hahn W.C., Getz G., Mills G.B., Boehm J.S., Golub T.R., Garraway L.A., Sellers W.R.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature 569:503-508(2019)

PubMed=31160637; DOI=10.1038/s41598-019-44491-x
Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M., MacLeod R.A.F., Nagel S., Steube K., Uphoff C.C., Drexler H.G.
The LL-100 panel: 100 cell lines for blood cancer studies.
Sci. Rep. 9:8218-8218(2019)

Cross-references
Cell line collections AddexBio; C0003031/4985
ATCC; CRL-8286
BCRJ; 0321
CLS; 300320/p630_REH
DSMZ; ACC-22
Cell line databases/resources CLDB; cl4132
CCLE; REH_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CCRID; 3131C0001000700131
Cell_Model_Passport; SIDM00447
Cosmic-CLP; 909696
DepMap; ACH-000960
GDSC; 909696
LINCS_LDP; LCL-1039
Lonza; 58
Ontologies BTO; BTO:0001163
CLO; CLO_0008781
CLO; CLO_0008782
Biological sample resources BioSample; SAMN03471040
BioSample; SAMN03473380
BioSample; SAMN10988185
Chemistry resources ChEMBL-Cells; CHEMBL3308823
ChEMBL-Targets; CHEMBL2366320
PharmacoDB; REH_1299_2019
Gene expression databases ArrayExpress; E-MTAB-2770
ArrayExpress; E-MTAB-3610
ArrayExpress; E-MTAB-7721
ArrayExpress; E-MTAB-7722
GEO; GSM236802
GEO; GSM236838
GEO; GSM482492
GEO; GSM499514
GEO; GSM499538
GEO; GSM499727
GEO; GSM499733
GEO; GSM887530
GEO; GSM888612
GEO; GSM931330
GEO; GSM931331
GEO; GSM1195448
GEO; GSM1374847
GEO; GSM1670369
Other Wikidata; Q29958043
Polymorphism and mutation databases Cosmic; 798668
Cosmic; 801720
Cosmic; 909696
Cosmic; 919149
Cosmic; 991551
Cosmic; 994183
Cosmic; 996287
Cosmic; 998706
Cosmic; 999751
Cosmic; 1012114
Cosmic; 1037725
Cosmic; 1067440
Cosmic; 1118468
Cosmic; 1130244
Cosmic; 1191700
Cosmic; 1483360
Cosmic; 1524815
Cosmic; 2491075
Cosmic; 2523595
Cosmic; 2649233
LiGeA; CCLE_618
Entry history
Entry creation04-Apr-2012
Last entry updated06-Sep-2019
Version number29